Claims

1. Use of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide in the manufacture of a medicament for the treatment of pain associated with osteoarthritis in the knee in patients with effusion.

2. The use of (2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 1, wherein the patients are patients with effusion and synovitis.

3. The use of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to anyone of claim 1 or 2, wherein the medicament is to be administered as a single intra-articular dose.

4. The use of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 3, wherein the single intra-articular dose is from 15 to 60 mg.

5. The use of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide according to claim 4, wherein the single intra-articular dose is 60 mg.

6. Use of a pharmaceutical composition comprising an effective amount of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide as active ingredient and pharmaceutically acceptable excipients in the manufacture of a medicament for the treatment of pain associated with osteoarthritis in the knee in patients with effusion.

7. The use according to claim 6, wherein the patients are patients with effusion and synovitis.

8. The use according to claim 6, wherein the effective amount is from 15 to 60 mg.

9. Use according to claim 7, wherein the effective amount is 60 mg.

10. An article of manufacture comprising:

- a packaging material;

- a pharmaceutical composition comprising 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide as active ingredient and pharmaceutically acceptable excipients; and

- a label or package insert contained within the packaging material indicating that patients receiving the treatment with the above mentioned pharmaceutical composition can be treated for the treatment of pain associated with osteoarthritis in the knee in patients with effusion.